1
Participants
Start Date
January 14, 2020
Primary Completion Date
July 8, 2021
Study Completion Date
July 8, 2021
lorlatinib
continued daily administration of 100 mg lorlatinib
lorlatinib
continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
lorlatinib
continued daily administration of 100 mg QD lorlatinib
lorlatinib
continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
lorlatinib
continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
Emory University Hospital, Atlanta
Investigational Drug Service, Atlanta
The Emory Clinic, Atlanta
Winship Cancer Institute, Emory University, Atlanta
Mays Cancer Center, San Antonio
University Health System, San Antonio
University of Colorado Denver CTO (CTRC), Aurora
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora
University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP), Aurora
University of Colorado Hospital, Anschutz Outpatient Pavilion (AOP), Aurora
Lead Sponsor
Pfizer
INDUSTRY